Neuroblastoma MedDRA version: 16.1 Level: LLT Classification code 10029261 Term: Neuroblastoma NOS System Organ Class: 100000004864
Conditions
Interventions
Product Name: Temozolomide
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Temozolomide
CAS Number: 85622-93-1
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration numbe
Sponsors
The University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Disease specific ? Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS) definition ? Relapsed or refractory neuroblastoma o Relapsed: any relapsed or progressed high-risk neuroblastoma o Refractory high risk disease: Lack of adequate response to frontline therapy that precludes the patient from proceeding to consolidation therapies (e.g myeloablative chemotherapy) ? Measurable disease by cross sectional imaging (RECIST) or evaluable disease (uptake on MIBG scan with or without bone marrow histology). Patients with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study General ? Age ?1 to ?21 years ? Informed consent from patient, parent or guardian Performance and organ function ? Performance Status: o Lansky ? 50%, Karnofsky ? 50% or ECOG ?3 (Patients who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score) ? Life expectancy of ?12 weeks ? Bone marrow function (within 72 hours of eligibility assessment): o No bone marrow disease: ? Platelets ? 75 x 10e9/L (unsupported for 72 hours) ? ANC ? 0.75 x 10e9/L (no G-CSF support for 72 hours) ? Haemoglobin > 7.5 g/dL (transfusions allowed) o Bone marrow disease: ? Platelets ? 50 x109/L (unsupported for 72 hours) ? ANC ?0.5 x 10e9/L (no G-CSF for 72 hours) ? Haemaglobin > 7.5 g/dL (transfusions allowed) ? Renal function (within 72 hours of eligibility assessment): o Absence of clinically significant proteinuria (early morning urine dipstick ?2+). When the dipstick urinalysis shows a proteinuria > 2+, a protein:creatinine (Pr/Cr) ration must be =65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: ? Previous treatment with bevacizumab, temozolomide, irinotecan or any combination of these drugs ? Known hypersensitivity to: o Any study drug or component of the formulation o Chinese hamster ovary products or other recombinant human or humanised antibodies ? Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis) ? Any ongoing arterial thrombo-embolic events ? Patient less than (at point of eligibility assessment): o 48 hours post bone marrow aspirate/trephine o 48 hours post central line insertion o Four weeks post major surgery o One week post core biopsy o Two weeks from prior chemotherapy o Six weeks from prior craniospinal or MIBG therapy and two weeks from radiotherapy to the tumour bed o Eight weeks from prior myeloablative therapy with haempoietic stem cell rescue (autologous stem cell transplant) o Three months from prior allogeneic stem cell transplant o Two weeks from last administration of an IMP in an IMP-trial ? Bleeding metastases (Patients with CNS metastases can be enrolled as long as the metastases are not bleeding) ? Invasion of major blood vessels ? Use of enzyme inducing anticonvulsants within 72 hours of eligibility assessment ? History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation) ? History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment ? Pregnant or lactating patient ? Any uncontrolled medical condition that poses an additional risk to the patient (i.e. haemoptysis, non-healing, bone fracture, wound/ulcer) ? Low probability of treatment compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: - To test whether bevacizumab added to a backbone chemotherapy regimen (temozolomide or irinotecan-temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma - To test whether the addition of irinotecan to temozolomide increases the activity of chemotherapy in children with relapsed or refractory neuroblastoma;Secondary Objective: To evaluate the safety of the above therapy regimens and to compare how the combinations influence the frequency of relapsing and prolong the survival of treated patients.;Primary end point(s): Best response (Complete Response [CR], or Partial Response [PR]) at any time during the 6 cycles of trial treatment.;Timepoint(s) of evaluation of this end point: Response will be assessed after 2, 4 and 6 cycles of trial treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary Endpoints: - Safety of the combinations: Incidence and severity of Adverse Events (AE)s - Progression-free survival (PFS) - Overall survival (OS) Exploratory/Tertiary Endpoints: - Changes in magnetic resonance imaging (MRI) derived functional imaging biomarkers of angiogenesis measured by quantitative dynamic contrast enhanced (DCE) MRI: ? Primary biomarkers will be the transfer constant Ktrans [min-1] and initial area under the gadolinium uptake curve from 0 to 60 seconds (IAUGC60, mM Gd min) and secondary biomarkers will be tumour apparent diffusion coefficient (ADC, 10-6 cm2 s-1), native T1 and T2 relaxation times (ms) and transverse relaxation rate R2*. - Changes in circulating mRNA levels for TH, PHOX2B and DCX in bone marrow and blood samples - Pharmacokinetics of bevacizumab - Pilot descriptive study of angiogenesis markers that may include: o O6-methylguanine-methyltransferase (MGMT) status, immunohistochemistry and immunofluorescence markers on tumour samples (such as microvessel density (MVD), CD31, Ki67, NRP1, VEGFR-1, VEGFR-2, C-KIT), DNA/RNA extraction from tissue sections for tumour mutation screening and tumour expression profiling o Optional somatic DNA analysis of polymorphisms in genes implicated in angiogenesis and tumorigenesis (such as VEGFR1, VEGFA SNPs) o Levels and dynamics of circulating angiogenic cytokines throughout the treatment;Timepoint(s) of evaluation of this end point: Up until the last follow up | — |
Countries
Ireland, Spain, United Kingdom
Contacts
Public ContactUREC
INSTITUTO DE INVESTIGACION SANITARIA LA FE
Outcome results
None listed